Pioglitazone and bladder cancer: two studies, same database, two answers

Authors

  • Frank de Vries,

    Corresponding author
    1. School CAPHRI, Maastricht University, Maastricht, the Netherlands
    2. Department of Pharmacoepidemiology and Clinical Pharmacology Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
    • Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre +, Maastricht, the Netherlands
    Search for more papers by this author
  • Maurice Zeegers,

    1. Section of Complex Genetics, Department of Genetics and Cell Biology, University of Maastricht, Maastricht, the Netherlands
    Search for more papers by this author
  • Maria E. Goossens

    1. Department of General Practice, KU Leuven, Leuven, Belgium
    Search for more papers by this author

Correspondence

Dr Frank de Vries PharmD PhD, Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre, 6229 ER Maastricht, the Netherlands.

Tel.: +31 (0)43 387 6543

E-mail: frank.de.vries@mumc.nl

No abstract is available for this article.

Ancillary